metricas
covid
Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Effectiveness of nebulized hypertonic saline in patients with bronchial hypersec...
Journal Information
Vol. 160. Issue 1.
Pages 23-26 (January 2023)
Share
Share
Download PDF
More article options
Visits
4
Vol. 160. Issue 1.
Pages 23-26 (January 2023)
Brief report
Effectiveness of nebulized hypertonic saline in patients with bronchial hypersecretion
Efectividad del suero salino hipertónico nebulizado en pacientes con hipersecreción bronquial
Visits
4
Almudena González-Montaos
Corresponding author
, Cristina Ramos-Hernández, Irene Lojo-Rodríguez, Marta Núñez-Fernández, Alberto Fernández-Villar
Servicio de Neumología, Hospital Álvaro Cunqueiro; Área sanitaria de Vigo; Neumo I+i; Instituto de Investigación Biomédica de Galicia Sur (IISGS), Vigo, Pontevedra, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Abstract
Introduction

Nebulized hypertonic saline (HS) improves quality of life and reduces exacerbations in patients with cystic fibrosis. It is unknown if it would offer the same benefits in other hypersecretory pathologies.

Methods

Retrospective observational study. Patients who passed the tolerance test and started HS 5,8% with one year of follow-up were included. Clinical and healthcare parameters were quantified in the year before and after the start of treatment.

Results

101 patients, 60.4% women, 65 years (95% CI 62.4–67.9). 82 (81.2%) bronchiectasis, 6 (5.9%) COPD, 2 (2%) asthma, 1 (1%) ILD, and 10 (9.9%) other causes. There was a reduction in bronchorrhea (91.1% vs 75.2%), recurrent infections (57.4% vs 22.8%) and cycles of antibiotic therapy (1.54 vs 0.55), as well as as an increase in FEV1 (1881ml vs. 1942ml) and a decrease in visits to primary care (2.94 vs. 1.1), emergencies (0.36 vs. 0.17) and hospitalizations (0.17 vs. 0.17). 06). 73 patients (72.3%) presented an adequate tolerance.

Conclusion

Nebulization of HS 5,8% in patients with bronchial hypersecretion is safe and has a remarkable clinical and healthcare impact.

Keywords:
Bronchiectasis
Hypertonic saline
Sputum expectoration
Bronchial hypersecretion
Mucoactive treatment
Resumen
Introducción

El suero salino hipertónico (SSH) nebulizado mejora la calidad de vida y reduce las exacerbaciones en pacientes con fibrosis quística. Se desconoce si ofrecería los mismos beneficios en otras patologías hipersecretoras.

Métodos

Estudio observacional retrospectivo. Se incluyeron pacientes que superaron la prueba de tolerancia e iniciaron SSH 5,8% con un año de seguimiento. Se cuantificaron parámetros clínicos y asistenciales en los años previo y posterior al inicio del tratamiento.

Resultados

101 pacientes, 60,4% mujeres, 65 años (IC95% 62,4-67,9). 82 (81,2%) bronquiectasias, 6 (5,9%) EPOC, 2 (2%) asma, 1 (1%) EPID y 10 (9,9%) otros. Se evidenció una reducción de la broncorrea (91,1% vs 75,2%), las infecciones de repetición (57,4% vs 22,8%) y los ciclos de antibioterapia (1,54 vs 0,55), así como un aumento del FEV1 (1881ml vs 1942ml) y una disminución de las asistencias a atención primaria (2,94 vs 1,1), urgencias (0,36 vs 0,17) y hospitalizaciones (0,17 vs 0,06). 73 pacientes (72,3%) presentaron una adecuada tolerancia.

Conclusión

La nebulización de SSH 5,8% en pacientes con hipersecreción bronquial es segura y tiene un destacable impacto clínico y asistencial.

Palabras clave:
Bronquiectasias
Suero salino hipertónico
Expectoración
Hipersecreción bronquial
Tratamiento mucolítico

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.medcle.2023.06.013
No mostrar más